Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective

Journal of Controlled Release

Volumn 113, Issue 3, 2006, Pages 189-207

  Ratnam, D Venkat ^a   Ankola, D D ^a   Bhardwaj, V ^a   Sahana, D K ^a   Kumar, M N V Ravi ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Antioxidants; Biopharmaceutics; Controlled delivery; Intestinal permeability; Peroral; Pharmacokinetics; Solubility; Targeted delivery

Indexed keywords

CARDIOVASCULAR SYSTEM; COENZYMES; CONTROLLED DRUG DELIVERY; DISEASES; DRUG PRODUCTS; PATHOLOGY; PHARMACOKINETICS; SCAVENGING; SOLUBILITY;

BIOPHARMACEUTICS; CONTROLLED DELIVERY; INTESTINAL PERMEABILITY; PERORAL; TARGETED DELIVERY;

ANTIOXIDANTS;

3 INDOLEMETHANOL; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; ANTIOXIDANT; ASCORBIC ACID; CATALASE; CATECHIN; CHITOSAN; CYCLODEXTRIN; DECYLUBIQUINONE; ELLAGIC ACID; EPICATECHIN; EPIGALLOCATECHIN GALLATE; EUDRAGIT; FREE RADICAL; GENISTEIN; GLUTATHIONE PEROXIDASE; LIPOSOME; LYCOPENE; MACROGOL; MICROSPHERE; NANOPARTICLE; POLYMER; POLYVINYL ALCOHOL; PROTEIN DERIVATIVE; QUERCETIN; SCAVENGER; SUPEROXIDE DISMUTASE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARCINOMA; CHEMICAL MODIFICATION; CONTROLLED DRUG RELEASE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIET; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESPONSE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG TARGETING; HEART INFARCTION; HUMAN; HUNTINGTON CHOREA; HYPEROXIA; HYPERTENSION; INFLAMMATION; METASTASIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARTICLE SIZE; PATHOPHYSIOLOGY; PHARMACEUTICAL ENGINEERING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROPHYLAXIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SLOW DRUG RELEASE; SUSTAINED DRUG RELEASE;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR DISEASES; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; MITOCHONDRIA; NANOTECHNOLOGY; OXIDATIVE STRESS; PERMEABILITY; SOLUBILITY;

EID: 33745600868     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.04.015     Document Type: Review

References (148)

1. Sies H. Oxidative stress: oxidants and antioxidants. Exp. Physiol. 82 (1997) 291-295
2. Beckman K.B., and Ames B.N. The free radical theory of aging matures. Physiol. Rev. 78 (1998) 547-581
3. Gilgun-sherki Y., Melamed E., and Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40 (2001) 959-975
4. Azzi A., Davies K.J.A., and Kelly F. Free radical biology-terminology and critical thinking. FEBS Lett. 558 (2004) 3-6
5. Benzie I.F.F. Evolution of dietary antioxidants. Comp. Biochem. Physiol., A 136 (2003) 113-126
6. Eaton S.B., Eaton III S.B., and Konner M.J. Paleolithic nutrition revisited: a twelve year retrospective on its nature and implications. Eur. J. Clin. Nutr. 51 (1997) 207-216
7. Eaton S.B., konner M., and Shostak M. Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective. Am. J. Med. 84 (1988) 739-749
8. Milton K. Nutritional characteristics of wild primate foods: do the diets of our closest living relatives have lessons for us?. Nutrition 15 (1999) 488-498
9. Liu R.H. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr. 134 (2004) 3479S-3485S
10. Freeman B., and Crapo J. Biology of disease: free radicals and tissue injury. Lab. Invest. 47 (1987) 412-426
11. Beckman J., and Koppenol W. Nitric oxide, superoxide and peroxinitrite: the good, the bad and the ugly. Am. J. Physiol., Cell Physiol. 271 (1996) C1424-C1437
12. Halliwell B., and Gutteridge J.M. Lipid peroxidation, oxygen radicals, cell damage, and antioxidant therapy. Lancet (1984) 1396-1397
13. Christofidou-Solomidou M., and Muzykantov V.R. Antioxidant strategies in respiratory medicine. Treat. Res. Med. 5 (2006) 47-78
14. McCord J.M. Superoxide dismutase: rationale for use in reperfusion injury and inflammation. J. Free Radic. Biol. Med. 2 (1986) 307-310
15. Nishikawa M., Hyoudou K., Kobayashi Y., Umeyama Y., Takakura Y., and Hashida M. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J. Control. Release 109 (2005) 101-107
16. Giri S.N., and Misra H.P. Fate of superoxide dismutase in mice following oral route of administration. Med. Biol. 62 (1984) 285-289
17. Regnault C., Soursac M., Roch-Arveiller M., Postaire E., and Hazebroucq G. Pharmacokinetics of superoxide dismutase in rats after oral administration. Biopharm. Drug Dispos. 17 (1996) 174-195
18. Nishikimi M., and Yagi K. Molecular basis for the deficiency in humans of galonolactone oxidase, a key enzyme for ascorbic acid biosynthesis. Am. J. Clin. Nutr. 54 (1991) 1203S-1208S
19. Rozin P., Kabnick K., Pete E., Fischler C., and Shields C. The ecology of eating: smaller portion sizes in France than in the United States help explain the French paradox. Psychol. Sci. 14 (2003) 450-454
20. Curtis A.D., Murzilli S., Castelnuovo A.D., Rotilio D., Donati M.B., Gaetano G.D., and Iacoviello L. Alcohol-free red wine prevents arterial thrombosis in dietary-induced hypercholesterolemic rats: experimental support for the 'French paradox'. J. Thromb. Haemost. 3 (2005) 346-350
21. Chawla R. Regular drinking might explain the French paradox. Br. Med. J. 329 (2004) 1308
22. Ferrieres J. The French paradox: lessons for other countries. Heart 90 (2004) 107-111
23. Moreiras-Varela O. The Mediterranean diet in Spain. Eur. J. Clin. Nutr. 43 (1989) 83-87
24. Tur J.A., Romaguera D., and Pons A. Does the diet of the Balearic population, a Mediterranean-type diet, ensure compliance with nutritional objectives for the Spanish population?. Public Health Nutr. 8 (2005) 275-283
25. Scalbert A., and Williamson G. Dietary intake and bioavailability of polyphenols. J. Nutr. 130 (2000) 2073S-2085S
26. Brown J.E., Khodr H., Hider R.C., and Rice-Evans C.A. Structural dependence of flavonoid interactions with Cu+2 ions: implications for their antioxidant properties. Biochem. J. 330 (1998) 1173-1178
27. Setchell K.D., Brown N.M., Zimmer-Nechemias L., Brashear W.T., Wolfe B.E., Kirschner A.S., and Heubi J.E. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am. J. Clin. Nutr. 76 (2002) 447-453
28. Hollman P.C., Bijsman M.N., van Gameren Y., Cnossen E.P., de Vries J.H., and Katan M.B. The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radic. Res. 31 (1999) 569-573
29. Hackett A.M., Griffiths L.A., Broillet A., and Wermeille M. The metabolism and excretion of (+)-[14C]cyanidol-3 in man following oral administration. Xenobiotica 13 (1983) 279-286
30. Hof K.H.v.h., West C.E., Weststrate J.A., and Hautvast J.G.A.J. Dietary factors that affect the bioavailability of carotenoids. J. Nutr. 130 (2000) 503-506
31. Hadley C.W., Miller E.C., Schwartz S.J., and Clinton S.K. Tomatoes, lycopene, and prostate cancer:progress and promise. Exp. Biol. Med. 227 (2002) 869-880
32. Boileau A.C., Merchen N.R., Wasson K., Atkinson C.A., John J., and Erdman W. Cis-lycopene is more bioavailable than trans-lycopene in vitro and in vivo in lymph-cannulated ferrets. J. Nutr. 129 (1999) 1176-1181
33. Boileau T.W., Boileau A.C., and Erdman J.J.W. Bioavailability of all-trans and cis-isomers of lycopene. Exp. Biol. Med. 227 (2002) 914-919
34. Re R., Fraser P., Long M., Brameley P., and Rice-Evans C. Isomerization of lycopene in the gastric milieu. Biochem. Biophys. Res. Commun. 281 (2001) 576-581
35. Nguyen M., and Schwartz S. Lycopene stability during food processing. Proc. Soc. Exp. Biol. Med. 218 (1998) 101-105
36. Piskula M.K. Factors affecting flavonoids absorption. BioFactors 12 (2000) 175-180
37. Piskula M.K., Yamakoshi J., and Iwai Y. Daidzen and genistein but not their glucosides are absorbed from the rat stomach. FEBS Lett. 447 (1999) 287-291
38. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
39. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
40. Thompson T.N. Early ADME in support of drug discovery: the role of metabolic stability studies. Curr. Drug Met. 1 (2000) 215-241
41. Stahl W., and Sies H. Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans. J. Nutr. 122 (1992) 2161-2166
42. Bala I., Bharadwaj V., Hariharan S., Sitterberg J., Bakowsky U., and Kumar M.N.V.R. Design of biodegradable nanoparticles: a novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 16 (2005) 2819-2822
43. Bala I., Bhardwaj V., Hariharan S., and Kumar M.N.V.R. Analytical methods for assay of ellagic acid and its solubility studies. J. Pharm. Biomed. Anal. 40 (2006) 206-210
44. Viscovich M., lykkesfeldt J., and Poulsen H.E. Vitamin C pharmacokinetics of plain and slow release formulations in smokers. Clin. Nutr. 23 (2004) 1043-1050
45. Zhang L., Zheng Y., Chow M.S.S., and Zuo Z. Investigation of intestinal absorption and disposition of green tea catechins by caco-2 monolayer model. Int. J. Pharm. 287 (2004) 1-12
46. Teel R.W., and Martin R.M. Disposition of the plant phenol ellagic acid in the mouse following oral administration by gavage. Xenobiotica 18 (1988) 295-883
47. Whitley A.C., Stoner G.D., Darby M.V., and Walle T. Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid-extensive binding to protein and DNA. Biochem. Pharmacol. 66 (2003) 907-915
48. Su Y.L., Leung L.K., Huang Y., and Chen Z.-Y. Stability of tea theaflavins and catechins. Food Chem. 83 (2003) 189-195
49. Hong J., Lu H., Meng X., Ryu J.-H., Hara Y., and Yang C.S. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res. 62 (2002) 7241-7246
50. Zhou Q., Chiang H., Portocarrero C., Zhu Y., Hill S., Heppert K., Jayaratna H., Davies M., Janle E., and Kissinger P. Investigating the stability of EGCg in aqueous media. Curr. Sep. 20 (2003) 83-86
51. Proniuk S., Liederer B.M., and Blanchard J. Preformulation study of epigallocatechin gallate, a promising antioxidant for topical skin cancer prevention. J. Pharm. Sci. 91 (2002) 111-117
52. Matsuda Y., and Masahara R. Photostability of solid-state ubidecarnenone at ordinary and elevated temperatures under exaggerated UV irradiation. Pharm. Res. 72 (1983) 1198-1203
53. Melendez-Martinez A.J., Vicario I.M., and Heredia F.J. Stability of carotenoid pigments in foods [article in Spanish]. Arch. Latinoam. Nutr. 54 (2004) 209-215 (Abstract)
54. Pinto M.S., Lajolo F.M., and Genovese M.I. Effect of storage temperature and water activity on the content and profile of isoflavones, antioxidant activity, and in vitro protein digestibility of soy protein isolates and defatted soy flours. J. Agric. Food Chem. 16 (2005) 6340-6346
55. Chen L., Lee M.-J., Li H., and Yang C.S. Absorption, distribution and elimination of tea polyphenols in rats. Drug Metab. Dispos. 25 (1997) 1045-1050
56. Lambert J.D., Lee M.-J., Lu H., Meng X., Hong J.J.J., Seril D.N., Sturgill M.G., and Yang C.S. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J. Nutr. 133 (2003) 4172-4177
57. Cai Y., Anavy N.D., and Chow H.-H.S. Contribution of presystemic hepatic extraction to the low oral bioavailability of green tea catechins in rats. Drug Metab. Dispos. 30 (2002) 1246-1249
58. Brown M.J., Ferruzzi M.G., Nguyen M.L., Cooper D.A., Eldridge A.L., Schwartz S.J., and White W.S. Carotenoid bioavailability is higher from salads ingested with full-fat than with fat-reduced salad dressings as measured with electrochemical detection. Am. J. Clin. Nutr. 2004 (2004) 396-403
59. 10 content of the average Danish diet. Int. J. Vitam. Nutr. Res. 67 (1997) 123-129
60. 10 in a meal or as capsules to healthy subjects. Nutr. Res. 17 (1997) 941-945
61. Mallis L.M., Sarkahian A.B., Harris H.A., Zhang M.-Y., and McConnell O.J. Determination of rat oral bioavailability of soy-derived phytoestrogens using an automated on-column extraction procedure and electrospray tandem mass spectrometry. J. Chromatogr., B 796 (2003) 71-86
62. 13C-labeled tracers in premenopausal women. Am. J. Clin. Nutr. 77 (2003) 411-419
63. Setchell K.D.R., Brown N.M., Desai P., Zimmer-Nechemias L., Wolfe B.E., Brashear W.T., Kirschner A.S., Cassidy A., and Heubi J.E. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr. 131 (2001) 1362S-1375S
64. Lesser S., Cermak R., and Wolffram S. Bioavailability of quercetin in pigs is influenced by the dietary fat content. J. Nutr. 134 (2004) 1508-1511
65. Levine M., Conry-cantilena C., Wang Y., Welch R.W., Washko P.W., Dhariwal K.R., Park J.B., Lazarev A., Graumlich J.F., Kings J., and Cantilena L.R. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. 93 (1996) 3704-3709
66. Gustin D.M., Rodvold K.A., Sosman J.A., Diwadkar-Navsariwala V., Stacewicz M., Viana M., Crowell J.A., Murray J., Tiller P., and Bowen P.E. Single-dose pharmacokinetic study of lycopene delivered in a well-defined food-based lycopene delivery system (tomato paste-oil mixture) in healthy adult male subjects. Cancer Epidemiol. Biomark. Prev. 13 (2004) 850-860
67. Anderton M.J., Manson M.M., Verschoyle R.D., Gescher A., Lamb J.H., Farmer P.B., Steward W.P., and Williams M.L. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin. Cancer Res. 10 (2004) 5233-5241
68. Arts I.C.W., Sesink A.L.A., Faassen-Peters M., and Hollman P.C.H. The type of sugar moiety is a major determinant of the small intestinal uptake and subsequent biliary excretion of dietary quercetin glycosides. Br. J. Nutr. 91 (2004) 841-847
69. Day A.J., DuPont M.S., Ridley S., Rhodes M., Rhodes M.J.C., Morgan M.R.A., and Williamson G. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver l-glucosidase activity. FEBS Lett. 436 (1998) 71-75
70. Walle T., Otake Y., Walle U.K., and Wilson F.A. Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J. Nutr. 130 (2000) 2658-2661
71. Bokkenheuser V.D., Shackleton C.H.L., and Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal bacteroides from humans. Biochem. J. 248 (1987) 953-956
72. Silberberg M., Morand C., Manach C., Scalbert A., and Remesy C. Co-administration of quercetin and catechin in rats alters their absorption but not their metabolism. Life Sci. 77 (2005) 3156-3167
73. Tsukaguchi H., Tokui T., Mackenzie B., Berger U.V., Chen X.Z., Wang Y., Brubaker R.F., and Hediger M.A. A family of mammalian Na+-dependent l-ascorbic acid transporters. Nature 399 (1999) 70-75
74. Teel R.W. Distribution and metabolism of ellagic acid in the mouse following intraperitoneal administration. Cancer Lett. 34 (1987) 165-171
75. Teel R.W., Martin R.M., and Allahyari R. Ellagic acid metabolism and binding to DNA in organ explant cultures of the rat. Cancer Lett. 36 (1987) 203-211
76. Teel R.W., Stoner G.D., Babcock M.S., Dixit R., and Kim K. Benzo(alpha)pyrene metabolism and DNA-binding in cultured explants of human bronchus and in monolayer cultures of human bronchial epithelial cells treated with ellagic acid. Cancer Detect. Prev. 9 (1986) 59-66
77. Anupongsanugool E., Teekachunhatean S., Rojanasthien N., Pongsatha S., and Sangdee C. Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women. Clin. Pharmacol. 5 (2005) 2
78. Sfakianos J., Coward L., Kirk M., and Barnes S. Intestinal uptake and biliary excretion of the isoflavone genistein in rats. J. Nutr. 127 127 (1997) 1260-1268
79. Hacquebard M., and Carpentier Y.A. Vitamin E: absorption, plasma transport and cell uptake. Curr. Opin. Clin. Nutr. Metab. Care 8 (2005) 133-138
80. Meng X., Lee M.J., Li C., Sheng S., Zhu N., Sang S., Ho C.T., and Yang C.S. Formation and identification of 4′-O-methyl-(-)-epigallocatechin in humans. Drug Metab. Dispos. 29 (2001) 789-793
81. Morand C., Crespy V., Manach C., Besson C., Demigné C., and Sy C.R.m. Plasma metabolites of quercetin and their antioxidant properties. Am. J. Physiol. 275 (1998) R212-R219
82. Crespy V., Morand C., Manach C., Besson C., Demigne C., and Remesy C. Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am. J. Physiol. 277 (1999) G120-G126
83. Rubin S.H., DeRitter E., and Johnson J.B. Stability of vitamin C (ascorbic acid) in tablets. J. Pharm. Sci. 65 (1976) 963-968
84. Graumlich J.F., Ludden T.M., Conry-Cantilena C., Cantilena J.L.R., Wang Y., and Levine M. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm. Res. 14 (1997) 1133-1139
85. 10): Biochemical, functional, medical, and therapeutic aspects in human health and diseases vol. 1 (2001), Prominent Press, Scottsdale 143-150
86. Bangalore D., McGlynn W., and Scott D. Effect of beta-cyclodextrin in improving the correlation between lycopene concentration and ORAC values. J. Agric. Food Chem. 53 (2005) 1878-1883
87. Ficarra R., Tommasini S., Raneri D., Calabro` M.L., Bella M.R.D., Rustichelli C., Gamberini M.C., and Ficarra P. Study of flavonoids/β-cyclodextrins inclusion complexes by NMR, FT-IR, DSC, X-ray investigation. J. Pharm. Biomed. Anal. 29 (2002) 1005-1014
88. Abuchowski A., McCoy J.R., Palczuk N.C., Es T.V., and Davies F.F. Effect of covalent attachment of polyethylene glycol on immunogenecity and circulating life of bovine liver catalase. J. Biol. Chem. 252 (1977) 3582-3586
89. White C., Jackson J., Abuchowski A., Kazo G., Mimmack R., Berger E., Freeman B., McCord J., and Repine J. Poly-ethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats. J. Appl. Physiol. 66 (1989) 584-590
90. Muzykantov V.R. Targeting of superoxide dismutase and catalase to vascular endothelium. J. Control. Release 71 (2001) 1-21
91. 10 analog decylubiquinone inhibits the redox-activated mitochondrial permeability transition. J. Biol. Chem. 278 (2003) 49079-49084
92. Silva G.M., and Campos P.M. Ascorbic acid and its derivatives in cosmetic preparations. Cosmet. Toilet. 115 (2000) 59-62
93. Youk H.-J., Lee E., Choi M.-K., Lee Y.-J., Chung J.H., Kim S.-H., Lee C.-H., and Lim S.-J. Enhanced anticancer efficacy of a-tocopheryl succinate by conjugation with polyethylene glycol. J. Control. Release 107 (2005) 43-52
94. Kommuru T.R., Gurley B., Khan M.A., and Reddy I.K. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int. J. Pharm. 212 (2001) 233-246
95. Ljusberg-Wahren H., Nielsen F.S., Brogard M., Troedsson E., and Mullertz A. Enzymatic characterization of lipid-based drug delivery systems. Int. J. Pharm. 298 (2005) 328-332
96. Torchillin V. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev., Drug Discov. 4 (2005) 145-160
97. Chen H., Torchillin V., and Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. 13 (1996) 1378-1383
98. Stone W.L., and Smith M. Therapeutic uses of antioxidant liposomes. Mol. Biotechnol. 27 (2004) 217-230
99. Rengel R.i.G., Filipovic-Grcic J., Epelak I.C., anic-Grubisic T.Z., and Barisi K. The effect of liposomes with superoxide dismutase on A2182 cells. Eur. J. Pharm. Biopharm. 60 (2005) 47-51
100. Fang J., Hung C., Hwang T., and Huang Y. Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumaor administrations. J. Drug Target. 13 (2005) 19-27
101. Sinha J., Das N., and Basu M.K. Liposomal antioxidants in combating ischemia-reperfusion injury in rat brain. Biomed. Pharmacother. 55 (2001) 264-271
102. Minko T., Stefanov A., and Pozharov V. Selected contribution: lung hypoxia: antioxidant and antiapoptotic effects of liposomal α-tocopherol. J. Appl. Physiol. 93 (2002) 1550-1560
103. Fan J J., Shek P.N., Suntres Z.E., Li Y.H., Oreopoulos G.D., and Rotstein O.D. Liposomal antioxidants provide prolonged protection against acute respiratory distress syndrome. Surgery 128 (2000) 332-338
104. Suntres Z.E., and Shek P.N. Incorporation of alpha-tocopherol in liposomes promotes the retention of liposome-encapsulated glutathione in the rat lung. J. Pharm. Pharmacol. 46 (1994) 23-28
105. Giovagnoli S., Luca G., Casaburi I., Blasi P., Macchiarulo G., Ricci M., Calvitti M., Basta G., Calafiore R., and Rossi C. Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: in vitro effects on isolated neonatal porcine pancreatic cell clusters. J. Control. Release 107 (2005) 65-77
106. Setchell K.D., Brzezinski A., Brown N.M., Desai P.B., Melhem M., Meredith T., Zimmer-Nechimias L., Wolfe B., Cohen Y., and Blatt Y. Pharmacokinetics of a slow-release formulation of soybean isoflavones in healthy postmenopausal women. J. Agric. Food Chem. 53 (2005) 1938-1944
107. Ogawa Y., Kanatsu K., Iino T., Kato S., Jeong Y., Shibata N., Takada K., and Takeuchi K. Protection against dextran sulfate sodium-induced colitis by microspheres of ellagic acid in rats. Life Sci. 71 (2002) 827-839
108. Esposito E., Cervellati F., Menegatti E., Nastruzzi C., and Cortesi R. Spray dried Eudragit microparticles as encapsulation devices for vitamin C. Int. J. Pharm. 242 (2002) 329-334
109. Kumar M.N.V.R., Muzzarelli R.A.A., Muzzarelli C., Sashiwa H., and Domb A.J. Chitosan chemistry and pharmaceutical perspectives. Chem. Rev. 104 (2004) 6017-6084
110. Desai K.G., and Park H.J. Encapsulation of vitamin C in tripolyphosphate cross-linked chitosan microspheres by spray drying. J. Microencapsul. 2 (2005) 179-192
111. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv. Drug Deliv. Rev. 34 (1998) 221-233
112. Hussain N., Jaitley V., and Florence A.T. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 50 (2001) 107-142
113. Bhardwaj V., Hariharan S., Bala I., Lamprecht A., Kumar N., Panchagnula R., and Kumar M.N.V.R. Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J. Biomed. Nanotech. 1 (2005) 235-258
114. Kreuter J. Peroral administration of nanoparticles. Adv. Drug Deliv. Rev. 7 (1991) 71-86
115. Kreuter J. Nanoparticle-based drug delivery systems. J. Control. Release 16 (1991) 169-176
116. Kreuter J. Nanoparticles. In: Swarbrick J., and Boylan J.C. (Eds). Encyclopedia of pharmaceutical technology (1994), Marcel Dekker, New York 165-190
117. Brannon-Peppas L., and Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56 (2004) 1649-1659
118. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int. J. Pharm. 116 (1995) 1-9
119. Alonso M.J. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 58 (2004) 168-172
120. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
121. Hsu C., Cui Z., Mumper R.J., and Jay M. Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors. AAPS Pharm. Sci. Tech. 4 (2003) 1-12
122. 10-loaded PMMA nanoparticles by a new emulsification process based on microfluidization. Colloids Surf., A Physicochem. Eng. Asp. 210 (2002) 95-104
123. Bala I., Bhardwaj V., Hariharan S., Vo Kharade S., Roy N., and Ravi Kumar M.N.V. Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J. Drug Targeting 14 (2006) 27-34
124. Duclairoir C., Orecchioni A.-M., Depraetere P., Osterstock F., and Nakache E. Evaluation of gliadins nanoparticles as drug delivery systems: a study of three different drugs. Int. J. Pharm. 253 (2003) 133-144
125. Kristl J., Volk B., Gasperlin M., Sentjurc M., and Jurkovic P. Effect of colloidal carriers on ascorbyl palmitate stability. Eur. J. Pharm. Sci. 19 (2003) 181-189
126. Dziubla T.D., Karim A., and Muzykantov V.R. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J. Control. Release 102 (2005) 427-439
127. Muro S., Cui X., Gajewski C., Muriciano J.-C., Muzykantov V.R., and Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am. J. Physiol., Cell Physiol. 285 (2003) C1339-C1347
128. Ishida M., Sakai H., Sugihara S., Aoshima S., Yokoyama S., and Abe M. Controlled release of vitamin E from thermo-responsive polymeric physico-gel. Chem. Pharm. Bull. 51 (2003) 1348-1349
129. Renard D., Robert P., Lavenant L., Melcion D., Popineau Y., Gue'guen J., Duclairoir C., Nakache E., Sanchez C., and Schmitt C. Biopolymeric colloidal carriers for encapsulation or controlled release applications. Int. J. Pharm. 242 (2002) 163-166
130. Simo ̃es S.I., Delgado T.C., Lopes R.M., Jesus S., Ferreira A.A., Morais J.A., Cruz M.E.M., Corvo M.L., and Martins M.B.F. Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in transfersomes. J. Control. Release 103 (2005) 419-434
131. Boissinot M., Kuhn L., Lee P., Fisher C., Wang Y., Hallewell R., and Tainer J. Rational design and expression of a heparin-targeted human superoxide dismutase. Biochem. Biophys. Res. Commun. 190 (1993) 250-258
132. Reinholz M., Haggard J., Curran G., and Poduslo J. Plasma pharmacokinetics, nervous system biodistribution and biostability, and spinal cord permeability at the blood brain barrier of putrescine-modified catalase in the adult rat. Exp. Neurobiol. 159 (1999) 191-203
133. Fujita T., Nishika W., Tamaki C., Takakura Y., Hashida M., and Sezaki H. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. J. Pharm. Exp. Ther. 263 (1992) 971-978
134. Christofidou-Solomidou M., Scherpereel A., Wiewrodt R., Ng K., Sweitzer T., Arguiri E., Shuvaev V., Solomides C.C., Albelda S.M., and Muzykantov V.R. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am. J. Physiol., Lung Cell. Mol. Physiol. 285 (2003) L283-L292
135. Kozower B.D., Christofidou-solomidou M., Sweitzer T.D., Muro S., Buerk D.G., Solomides C.C., Albelda S.M., Patterson G.A., and Muzykantov V.R. Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat. Biotechnol. 21 (2003) 392-398
136. Ma S.-F., Nishikawa M., Katsumi H., Yamashita F., and Hashida M. Liver targeting of catalase by cationization for prevention of acute liver failure in mice. J. Control. Release 110 (2006) 273-282
137. Puleo A., Niemi R., Järvinen T., Puglisi G., and Pignatello R. Chemical and enzymatic stability evaluation of lipoamino acid esters of idebenone. Eur. J. Pharm. Biopharm. 57 (2004) 343-346
138. Orosz K.E., Gupta S., Hassink M., Abdel-Rahman M., Moldovan L., Davidorf F.H., and Moldovan N.I. Delivery of antiangiogenic and antioxidant drugs of ophthalmic interest through a nanoporous inorganic filter. Mol. Vis. 10 (2004) 555-565
139. Sheu S.-S., Nauduri D., and Anders M.W. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim. Biophys. Acta 1762 (2006) 256-265
140. Shea T.B., Ortiz D., Nicolosi R.J., Kumar R., and Watterson A.C. Nanosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta. J. Alzheimer's Dis. 7 (2005) 297-301
141. Naughton D.P. Drug targeting to hypoxic tissue using self-inactivating bioreductive delivery systems. Adv. Drug Deliv. Rev. 53 (2001) 229-233
142. Weydert C., Roling B., Liu J., Hinkhouse M.M., Ritchie J.M., Oberley L.W., and Cullen J.J. Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol. Cancer Ther. 2 (2003) 361-369
143. Danel C., Erzurum S., Prayssac P., Eissa N., Crystal R., Herve P., Baudet B., Mazmanian M., and Lemarchand P. Gene therapy for oxidant injury-related diseases: adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury. Hum. Gene Ther. 9 (1998) 1487-1496
144. Engelhardt J.F. Redox-mediated gene therapies for environmental injury. Antioxid. Redox Signal. 1 (1999) 5-27
145. Wang I.C., Tai L.A., Lee D.D., Kanakamma P.P., Shen C.K.-F., Luh T.-Y., Cheng C.H., and Hwang K.C. C60 and water-soluble fullerene derivatives as antioxidants against radical-initiated lipid peroxidation. J. Med. Chem. 42 (1999) 4614-4620
146. 60 derivatives on activated microglia. Brain Res. 940 (2002) 61-68
147. Lee B.M., and Park K.-K. Beneficial and adverse effects of chemopreventive agents. Mutat. Res. 523-524 (2003) 265-278
148. Lee S.H., Oe T., and Blair I.A. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science 292 (2001) 2083-2086